Aik Jiang Lau

Education

• BSc(Honours)(Pharm) (National University of Singapore)
• PhD(Pharmaceutical Sciences) (National University of Singapore)
• Postdoctoral Fellowship(Pharmaceutical Sciences and Pharmacology) (UBC)

Research interests

The overarching theme of my research program is to enhance our understanding of the mechanistic basis of individual variation in pharmacokinetics and pharmacodynamics. Specifically, the aim is to elucidate the various genetic and non-genetic factors (e.g., drugs, food, epigenetics, gastrointestinal microbiota) involved in regulating drug metabolism, transport, and action. Ultimately, my research program is to translate experimental findings to personalize pharmacotherapy by improving drug effectiveness and safety in the individual patient.

Selected awards and honours

• Postdoctoral Scientist Award - Division for Drug Metabolism and Disposition, American Society for Pharmacology and Experimental Therapeutics, Experimental Biology Annual Meeting, San Diego, California, USA, April 2012
• Emil A. Pfitzer Postdoctoral Award, Drug Discovery Toxicology Specialty Section, Society of Toxicology, Society of Toxicology Annual Meeting, San Francisco, California, USA, March 2012
• Best Presentation Award - Postdoctoral Research Category, International Society for the Study of Xenobiotics (ISSX), 4th Asia-Pacific Regional Meeting of ISSX, Tainan, Taiwan, April 2011.

Selected publications

• Tan WK, Tan ARY, Sivanandam P, Goh EJH, Yap ZP, Saburulla NF, Austin-Muttitt K, Mullins JGL, and Lau AJ. In vitro inhibition of human aldehyde oxidase activity by clinically relevant concentrations of gefitinib and erlotinib: Comparison with select metabolites, molecular docking analysis, and impact on hepatic metabolism of zaleplon and methotrexate. Journal of Pharmacology and Experimental Therapeutics 2020, 374: 295-307. [Selected by editors to be featured on the journal cover of the August 2020 issue]
• Chen S, Austin-Muttitt K, Zhang LH, Mullins JGL, Lau AJ. Inhibition of human aldehyde oxidase by bazedoxifene, lasofoxifene, and structural analogues: In vitro and in silico analyses and comparison with other selective estrogen receptor modulators. Journal of Pharmacology and Experimental Therapeutics 2019, 371: 75-86.
• Bansal S, Lau AJ. Inhibition of human sulfotransferase 2A1-catalyzed sulfonation of lithocholic acid, glycolithocholic acid, and taurolithocholic acid by selective estrogen receptor modulators and various analogues and metabolites. Journal of Pharmacology and Experimental Therapeutics 2019, 369: 389-405.
• Xie JR, Saburulla NF, Chen S, Wong SY, Yap ZP, Zhang LH, Lau AJ. Evaluation of carbazeran 4-oxidation and O⁶-benzylguanine 8-oxidation as catalytic markers of human aldehyde oxidase: Impact of cytosolic contamination of liver microsomes. Drug Metabolism and Disposition 2019, 47: 26-37.  [Selected by editors to be featured in the journal website in January 2019]
• Yip CKY, Bansal S, Wong SY, Lau AJ. Identification of galeterone and abiraterone as inhibitors of dehydroepiandrosterone sulfonation catalyzed by human hepatic cytosol, SULT2A1, SULT2B1b, and SULT1E1.  Drug Metabolism and Disposition 2018, 46: 470-482.

Name of research trainees underlined